All Curated Mutation Sites in HPV 
Back to Mutation Home

 The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HPV related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.


Browse Data by Virus Gene/Protein/Region, Disease OR Description
*Please select one option you are interested in, the page will be automatically redirected.
     
     

Click the button below to quickly view the viral genes/regions/protein for mutation

Show All
  
E1
  
E1^E4
  
E2
  
E5
  
E6
  
E7
  
L1
  
L2
  

Keyword: Uterine Cervical Neoplasms-18199779
ID PMID Mutation Gene/Protein/Region Encoding Gene/Protein Disease Description Detail
1 18199779 A7636C
LCR
Uterine Cervical Neoplasms
G
R
L
View
2 18199779 A7839C
LCR
Uterine Cervical Neoplasms
G
R
L
View
3 18199779 C13T
LCR
Uterine Cervical Neoplasms
G
R
L
View
4 18199779 C7678T
LCR
Uterine Cervical Neoplasms
G
R
L
View
5 18199779 C7689A
LCR
Uterine Cervical Neoplasms
G
R
L
View
6 18199779 C7764T
LCR
Uterine Cervical Neoplasms
G
R
L
View
7 18199779 C7792T
LCR
Uterine Cervical Neoplasms
G
R
L
View
8 18199779 G7521A
LCR
Uterine Cervical Neoplasms
G
R
L
View
9 18199779 G7799A
LCR
Uterine Cervical Neoplasms
G
R
L
View
10 18199779 G7826A
LCR
Uterine Cervical Neoplasms
G
R
L
View
11 18199779 T7714G
LCR
Uterine Cervical Neoplasms
G
R
L
View
12 18199779 T7743G
LCR
Uterine Cervical Neoplasms
G
R
L
View
13 18199779 A6667C
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
14 18199779 A6691G
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
15 18199779 A6695C
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
16 18199779 A6803T
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
17 18199779 A6924C
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
18 18199779 A6964C
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
19 18199779 C6906T
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
20 18199779 K442N
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
21 18199779 Q429P
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
22 18199779 S423F
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
23 18199779 T389S
L1
L1
Uterine Cervical Neoplasms
G
R
L
View
24 18199779 E35E
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
25 18199779 G666A
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
26 18199779 I76I
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
27 18199779 I89I
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
28 18199779 T732C
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
29 18199779 T789C
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
30 18199779 T78T
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
31 18199779 T795G
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
32 18199779 T828C
E7
E7
Uterine Cervical Neoplasms
G
R
L
View
33 18199779 A289G
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
34 18199779 A532G
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
35 18199779 A61A
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
36 18199779 C335T
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
37 18199779 G145T
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
38 18199779 H78Y
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
39 18199779 L83V
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
40 18199779 Q14H
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
41 18199779 S142T
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
42 18199779 S143S
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
43 18199779 T286A
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
44 18199779 T350G
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
45 18199779 T527A
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
46 18199779 V62V
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
Contents
Description

The table shows all curated mutation sites of HPV in each literature

Table Description Column Note
D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.
G
The study mentioned the virus genotype/subtype information.
R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.
S
The study provided sequence information or accession numbers.
L
The study provided the geographic region/country of data origin.
C
The study provided clinical baseline information.
I
The study involved information related to immune.
T
The study involved host target genes.